REGENXBIO Inc. (NASDAQ:RGNX) Stock Has Consensus Price Target of $23.27

REGENXBIO Inc. (NASDAQ:RGNX) has been assigned a consensus recommendation of “Moderate Buy” from the thirteen analysts that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and nine have assigned a buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $23.27.

A number of equities analysts recently issued reports on RGNX shares. Wall Street Zen raised shares of REGENXBIO from a “strong sell” rating to a “hold” rating in a research note on Saturday, August 8th. Robert W. Baird cut their price objective on REGENXBIO from $32.00 to $29.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 25th. Morgan Stanley reiterated an “overweight” rating and set a $18.00 target price on shares of REGENXBIO in a report on Friday, August 7th. Leerink Partners increased their target price on REGENXBIO from $17.00 to $18.00 and gave the stock an “outperform” rating in a research report on Monday, June 22nd. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of REGENXBIO in a research note on Friday, September 4th.

REGENXBIO Price Performance

NASDAQ:RGNX opened at $7.40 on Wednesday. The firm’s fifty day simple moving average is $9.53 and its 200 day simple moving average is $9.18. The stock has a market cap of $488.47 million, a P/E ratio of -1.95 and a beta of 0.94. REGENXBIO has a twelve month low of $5.45 and a twelve month high of $16.19.

REGENXBIO (NASDAQ:RGNX) last issued its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.08 by $0.35. The business had revenue of $108.02 million during the quarter, compared to analyst estimates of $97.63 million. REGENXBIO had a negative net margin of 112.58% and a negative return on equity of 220.07%. On average, analysts expect that REGENXBIO will post -3.91 EPS for the current fiscal year.

Insiders Place Their Bets

In other REGENXBIO news, insider Steve Pakola sold 2,161 shares of the stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $13.64, for a total value of $29,476.04. Following the completion of the transaction, the insider owned 213,009 shares in the company, valued at approximately $2,905,442.76. This represents a 1.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 14.22% of the stock is currently owned by insiders.

Institutional Trading of REGENXBIO

A number of hedge funds have recently modified their holdings of the business. Versant Capital Management Inc raised its stake in REGENXBIO by 60.4% during the 2nd quarter. Versant Capital Management Inc now owns 2,741 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 1,032 shares during the last quarter. Diversified Trust Co boosted its stake in shares of REGENXBIO by 15.9% in the 1st quarter. Diversified Trust Co now owns 15,499 shares of the biotechnology company’s stock worth $130,000 after buying an additional 2,121 shares during the last quarter. Quantbot Technologies LP bought a new stake in shares of REGENXBIO in the second quarter worth $51,000. Legal & General Group Plc bought a new stake in shares of REGENXBIO in the second quarter worth $56,000. Finally, Entropy Technologies LP purchased a new stake in REGENXBIO during the first quarter valued at $87,000. Institutional investors own 88.08% of the company’s stock.

REGENXBIO Company Profile

REGENXBIO Inc is a biotechnology company focused on developing gene therapies for serious diseases with limited treatment options. The company uses its proprietary NAV AAV Gene Delivery Platform to design adeno-associated virus (AAV) vectors intended to deliver therapeutic genes to targeted cells and tissues.

REGENXBIO’s pipeline has included investigational therapies for rare and genetic disorders, including Duchenne muscular dystrophy, Hunter syndrome, severe mucopolysaccharidosis type I, and homozygous familial hypercholesterolemia.